Skip to content.

Andrew Elder

Deputy Managing Partner

HealthTech UCL Tech Fund

Joined 2005


Andrew is Deputy Managing Partner at AlbionVC. The veteran investor, who focuses on the digital health and life-sciences sectors, is a former neurosurgeon who has brought his valuable perspectives to the team since 2005. 

Why did Andrew make the switch from clinical medicine to healthtech investing? He was driven by a powerful desire to bring life-changing innovation to patients around the world, at scale.

Today he brings his expert knowledge to the boards of companies revolutionising healthcare from mental health and neuro-rehab to imaging and diagnostics, and bringing innovation to pharma companies from data and analytics to patient engagement. He also oversees management of the UCL Technology Fund, a long-standing partnership between AlbionVC and UCL Business. The fund helps ensure that academic innovations can reach society and transform lives. 

Before joining AlbionVC, Andrew worked at Boston Consulting Group and in the NHS. He holds degrees in Medicine and Surgery from the University of Cambridge and is a Fellow of the Royal College of Surgeons.


Andrew has recently exited from a high-pressure investment into his own health – his pursuit of a series of endurance sports. The father-of-three says he is now most at peace when exercising a little more gently. He can often be found on a board or boat, on a bike, or half-way up a mountain. The AlbionVC leader also spends time helping others via a range of mentoring and charitable roles. 

From Stephen Grellet, a 19thCentury Quaker missionary:

“ I shall pass through this world but once. Any good therefore that I can do or any kindness that I can show to any human being, let me do it now. Let me not defer or neglect it, for I shall not pass this way again.”


Featured content

Healios raises £7m from AlbionVC and InHealth Ventures to expand its life-changing digital mental health services 

Read the article >

Decentralised clinical trials platform uMotif announces new $25.5m investment

Read the article >
MyMeds&Me announces exit to a private equity portfolio company

MyMeds&Me announces exit to a private equity portfolio company  

Read the article >